Liraglutide is additionally approved for the treatment of obesity, at a dose of 3.0 mg (128), while semaglutide is in clinical development as a treatment for obesity (phase 3) and NASH (phase 2)
Siskind DJ, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, et al
Why BPC-157s Mechanism Matters More Than Its Half-Life Understanding how BPC-157 works is essential to understanding why half-life is largely irrelevant
They can damage skin cells, leading to premature ageing, dryness, and irritation
Med Cell Longev (2018) 2018:110
While Mounjaro is not a magic bullet, it certainly can be a game changer in overcoming barriers with weight loss & metabolic health